Did You Give Your DNA To 23andMe? Here’s Why You Might Regret It Soon

Amid financial challenges, DNA testing company 23andMe is reportedly exploring a potential sale, which could place the genetic data of over 15 million customers in the hands of new ownership.

The implications of this sale are significant, raising concerns over data privacy and the potential misuse of sensitive genetic information.

What’s at Stake?

23andMe’s genetic database, built over nearly two decades, includes a wealth of information about customers’ health predispositions and ancestral backgrounds.

While the company’s privacy policies claim to prioritize customer consent, a sale could result in a new owner with different priorities.

This change may impact how customers’ DNA data is utilized, potentially opening the door to various uses not initially agreed to by users, including by insurance companies, pharmaceutical firms or law enforcement agencies.

Privacy Concerns and Legal Issues

In an interview with NPR, Law professor Anya Prince from the University of Iowa’s College of Law said that those worried about their sensitive DNA information may not realize just how few federal protections exist.

Prince, who focuses on genetic privacy, said in the interview that, “HIPAA does not protect data that’s held by direct-to-consumer companies like 23andMe.”

The Health and Insurance Portability and Accountability Act, known as HIPAA, doesn’t apply to the 23andMe because HIPAA does not protect data held by direct-to-consumer companies.

Although U.S. law, specifically the Genetic Information Nondiscrimination Act, restricts the use of genetic data by health insurers and employers, it does not extend to life or disability insurers. This leaves a critical gap, potentially enabling future owners of the data to leverage it in ways customers didn’t anticipate.

The Broader Implications

This potential sale shines a spotlight on the ethical considerations surrounding consumer genetic data. Genetic information is unique and irreversible, making its protection vital.

As companies like 23andMe navigate financial pressures, customers must consider the long-term implications of sharing their DNA. Once data is shared, it becomes nearly impossible to control how it will be used in the future.

The possible sale of 23andMe underscores the challenges of balancing commercial interests with the privacy rights of customers.

As the future of genetic data sharing unfolds, consumers may need to rethink the costs and benefits of submitting their DNA to companies whose ownership and data policies could change unexpectedly.

The evolving landscape of genetic data privacy serves as a reminder to carefully consider the risks involved in sharing one’s most personal information.